Article
The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
Oncology reports - 1 Jul 2020
Du Wenwen, Sun Lin, Liu Ting, Zhu Jianjie, Zeng Yuanyuan, Zhang Yang, Wang Xueting, Liu Zeyi, Huang Jian-An
Abstract excerpt
Gefitinib is currently the preferred treatment for non‑small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)‑activating mutation. However, some patients gradually develop acquired resistance after receiving treatment. In addition to secondary T790M mutation, the remaining mechanisms contributing to non‑T790M mutations need to be explored. In the present study, NSCLC‑derived HCC827...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.